Summarized by Masters of Longevity from Longevity Technology.
Cell-based mRNA manufacturing gets profiled in an article examining a startup’s platform and its potential to enable repeat-dosed therapeutic approaches.
Key Takeaways
- Sensible Biotechnologies raised $47 million including Series A and up to $20 million in non-dilutive EU and Slovak funding.
- The company uses engineered eukaryotic cells and its PromPT capture method to produce mRNA with reportedly undetectable dsRNA and lower cytokine activation.
- Sensible partnered with Sartorius and added board representation from Oxford Science Enterprises and Recode Ventures to scale toward clinical-grade manufacturing.
